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Abstract
The m opioid receptor gene, OPRM1, undergoes extensive alternative pre-mRNA splicing in rodents and humans, with
dozens of alternatively spliced variants of the OPRM1 gene. The present studies establish a SYBR green quantitative PCR
(qPCR) assay to more accurately quantify mouse OPRM1 splice variant mRNAs. Using these qPCR assays, we examined the
expression of OPRM1 splice variant mRNAs in selected brain regions of four inbred mouse strains displaying differences in m
opioid-induced tolerance and physical dependence: C56BL/6J, 129P3/J, SJL/J and SWR/J. The complete mRNA expression
profiles of the OPRM1 splice variants reveal marked differences of the variant mRNA expression among the brain regions in
each mouse strain, suggesting region-specific alternative splicing of the OPRM1 gene. The expression of many variants was
also strain-specific, implying a genetic influence on OPRM1 alternative splicing. The expression levels of a number of the
variant mRNAs in certain brain regions appear to correlate with strain sensitivities to morphine analgesia, tolerance and
physical dependence in four mouse strains.
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Introduction
Morphine and most clinical analgesic agents, as well as heroin,
act primarily through m opioid receptors [1]. However, their
actions, such as analgesia, tolerance, physical dependence and
other side-effects vary among patients [2–4]. Similar effects have
been observed in animal models [5–9]. These observations are
consistent with the concept of subtypes of m opioid receptors that
was initially proposed by pharmacological studies [10–12] and
subsequently confirmed with the isolation of a multitude of m
opioid receptor variants generated by alternative splicing [13–17]
in rodents and humans despite the presence of a single m opioid
receptor gene, as determined by chromosomal mapping [18–21]
and genomic sequencing. Alternative pre-mRNA splicing is a
major mechanism for generating protein diversity and is exten-
sively used by the m opioid receptor gene. To date, studies show
that the mouse, rat and human OPRM1 genes generate 29, 16
and 19 splice variants, respectively, with similar patterns (Fig. 1)
(see reviews: [16,22] ). These splice variants can be categorized
into three major groups based upon receptor structure: 1) Full-
length carboxyl (C-) terminal variants with 7-transmembrane (7-
TM) domains; 2) Truncated variants containing 6-TM domains;
and 3) Truncated variants containing a single TM. The full length
7-TM C-terminal variants differ in their region-specific expres-
sions, receptor phosphorylation, internalization, and post-endo-
cytic sorting [23–31]. Furthermore, the intrinsic activities of m
drugs vary from variant to variant [32]. The significance of the
exon 11-associated 6-TM variants is illustrated by their role in the
analgesic actions of opioids such as morphine-6b-glucuronide
(M6G), fentanyl and heroin [33], as a novel new class of opioid
analgesics lacking many of the side-effects of traditional opiates
[34].
The sensitivity of mice towards m opioids on a variety of
phenotypic measures is genotype dependent [35–40]. For exam-
ple, surveys of inbred mouse strains reveal differences in morphine
dependence, assessed with naloxone-precipitated withdrawal
jumping scores, and tolerance, as seen by analgesic potency shifts
after chronic morphine administration [35,36,41]. 129P3/J mice
are highly refractory to morphine tolerance and naloxone-
precipitated withdrawal, whereas C57BL/6J and SWR/J mice
develop significant morphine tolerance and physical dependence.
These inbred mouse strains also show similar differences in
naloxone-precipitated withdrawal jumping scores toward other m
opioids including heroin [37], M6G and methadone [42].
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Figure 1. Schematic of the mouse OPRM1 gene structure, alternative splicing and predicted protein structures. A, Genomic structure of
the mouse OPRM1gene. Exons and introns are showed by boxes and horizontal lines, respectively. Intron size is indicated below the introns as
kilobases (kb). Promoters are showed by arrows. Exons are numbered based upon the published data. B, Alternative splicing of C-terminal splice
variants with 7-TM domains. Translational start and termination sites are indicated by downward and upward lines on exon boxes, respectively. The
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However, it is not clear how the genetic background of these
strains influences the expression of the OPRM1 gene, a primary
candidate responsible for the actions of m drugs seen in these
strains.
Our previous studies suggested region-specific alternative
splicing of the OPRM1 gene among brain regions using regular
RT-PCR approaches [25–28]. However, regular PCR can only
provide estimates of quantification due to technical limitations. To
establish more accurate, reliable and sensitive assays for quanti-
fying OPRM1 variant mRNAs we have established SYBR green
quantitative PCR (qPCR) assays for the OPRM1 splice variants.
Using these qPCR assays, we examined the expression levels of
OPRM1 splice variant mRNAs in selected brain regions of four
inbred mouse strains: C56BL/6J (B6), 129P3/J (129), SJL/J (SJL)
and SWR/J (SWR).
Materials and Methods
Animal
C56BL/6J (B6, stock #: 000664), 129P3/J (129, stock#:
000690), SJL/J (SJL, stock #: 000686) and SWR/J (SWR, stock
#: 000689) male mice at 7–8 weeks of age were obtained from
Jackson Laboratory. All mice were housed in groups of five,
maintained on a 12-h light/dark cycle and given ad libitum access
to food and water. All animal studies were approved by the
Institutional Animal Care and Use Committee of the Memorial
Sloan-Kettering Cancer Center.
Tissue dissection, RNA extraction and reverse-
transcription (RT)
Brain regions including the prefrontal cortex (Pfc), striatum
(Str), thalamus (Tha), hypothalamus (Hyp), hippocampus (Hip),
brain stem (BS), periaqueductal gray (PAG), and cerebellum (Cb)
were dissected on a mouse Plexiglas brain mold using the atlas of
Paxinos and Franklin [43] as a reference. The spinal cord (Spc)
from L1 to L5 and whole brain were also dissected. The dissected
tissues were immediately homogenized in QiAzol Reagent
(Qiagen). The homogenates were stored at 280uC until further
RNA isolation. 2–3 mice were pooled for each region, and a total
of 8–10 mice used for each strain. Total RNAs were extracted
using miRNeasy kit (Qiagen) following manufacture protocol.
RNA concentrations were determined using a Qubit 2.0
Fluorometer (Invitrogen). RNAs were first treated with Turbo-
DNA free reagent (Ambion) following the manufacture’s protocol
to remove potentially contaminating genomic DNA, and reverse
transcribed with Superscript II reverse transcriptase (Invitrogen)
and random hexmers. The first-strand cDNA was then used as
templates in SYBR qPCRs.
Primer design and SYBR green qPCR
Since many exons are shared by different variants, it is difficult
to design the short amplicon required for an efficient qPCR using
the TaqMan assay for most of the splice variants. SYBR Green
qPCR offers more flexibility in terms of amplicon size and thermo-
cycle conditions. Using primer design tools in GeneRunner and
VectorNTI, we designed appropriate primers for each splice
variants, optimized qPCR parameters, such as annealing temper-
ature and extension time, and obtained reasonable amplification
efficiency by generating standard curves using 5–7 serial 10-fold
dilutions of corresponding cDNAs as templates (Table S1). In most
cases, we designed primers targeting exon-exon junctions or
crossing at least two exons to obtain specific amplification.
Specificities of the primers were verified by qPCRs using plasmid
constructs containing corresponding variant cDNAs, and by
melting curve analysis and agarose gel analysis after qPCR. Table
S1 lists the names, sequences and location of primers, as well as
amplicon size, efficiency and PCR parameters, for all 29 splice
variants. Two workstations in two separate rooms were used
exclusively for qPCR to avoid cross contamination. Three
reference genes, succinate dehydrogenase subunit A (SDHA),
TATA box binding protein (TBP) and glycerakdehyde 3-
phosphate dehydrogenase (G3PDH), were selected to obtain
normalization factors using the formula[44–46]: Normalization
factor (NF) = (C(t)SDHA 6 C(t)TBP 6 C(t)G3PDH)
1/3. All qPCRs
were performed using HotStart-IT SYBR Green qPCR Master
Mix (USB, Affymetrix, INC) with Opticon 2 DNA Engine System
(Bio-Rad). Normalized expression (NE) or expression level for each
variant was calculated using the formula [44]: NEvariant = E
2(C(t)-
variant – C(t)NF) (E2DC(t)), where E is efficiency. Fold change (FC) was
calculated using the formula [44]: FC=NEvariant/NEreference,
where a reference was mE1/2 and is was defined as 100%.
mE1/2 amplified with primers from exon 1 to exon 2 represented
all C-terminal variants, including the original mMOR-1. Although
the original mMOR-1 transcribed through the exon 1 promoter is
by far the most abundant, it is difficult to design a pair of specific
primers for amplifying the exon 1 promoter-driven mMOR-1,
since exons 1–4 are shared by several other variants as well.
Statistical analysis
Data are represented as the mean 6 S.E.M. from at least three
independent experiments. Two-way ANOVA with Tukey’s
multiple comparisons test was used for analyzing qPCR data.
Statistical significance was set at p,0.05. The results are listed in
Table S3.
Results
Expression levels of OPRM1 splice variant mRNAs in four
inbred mouse strains
Using the established RT-SYBR green qPCR assays, we
examined the expression levels of OPRM1 splice variant mRNAs
in nine brain regions of four inbred mouse strains. The overall
expression levels among the variants are shown in a heatmap
clustered based upon Z-scores from the values (Log2 (E
2DC(t)) of
individual variants across different strains/regions, plotting from
the highest level (left, red) to the lowest level (right, green) (Fig. 2)
(All E2DC(t) values are listed in Table S2). The heatmap reveals a
wide range of expression levels among the variants, as indicated by
Z-score values from,24 to .4. mE1-2, which represents the
entire repertoire of full-length 7-TM variants, was expressed at the
highest level in all brain regions and strains. The expression of the
other splice variants differed dramatically among the regions and
strains.
To visualize expression patterns more closely, we compared five
C-terminal splice variants and two 6-TM and two 1-TM variants,
as well as mE1-2, by plotting their (21)/log2(E
2DC(t)) values in the
brain regions (Fig. 3). The various splice variant expression levels
among the brain regions ranged widely. For example, in the
lines between exons are introns that are spliced out during splicing. Predicted receptor structures are inserted at the right with colored bars
indicating different coding exons. C, Alternative splicing of truncated variants with 6-TM domains. D, Alternative splicing of truncated variants with 1-
TM domain.
doi:10.1371/journal.pone.0111267.g001
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hypothalamus of 129 mice, the relative expression levels ranged
from 0.1% for mMOR-1M to 22% for mMOR-1A, when their
E2DC(t) values were used to compare with those of mE1-2
designated as 100% (Fig. 3 & Table S2). The full length C-
terminal splice variants mMOR-1A and mMOR-1B1 in 129 mice
were highly expressed among most brain regions, corresponding to
approximately 10–20% of mE1-2 levels in their E2DC(t) values
(Fig. 3 & Table S2). On the other hand, in 129 mice the levels of
the truncated 6-TM variant mMOR-1G and mMOR-1M and
single TM variants, mMOR-1S and mMOR-1T, and the full
length mMOR-1D, ranged from about 0.1% to 5% of mE1-2
levels (Fig. 3 & Table S2). Similar expression patterns were
observed in other mouse strains (Fig. 3 & Table S2).
Region-specific expressions of OPRM1 splice variant
mRNAs in four inbred mouse strains
Overall, expression levels in whole brain were not predictive of
strain differences in specific regions. Within each strain, there are
major differences in the regional expression of the variants. The
heatmap segregating the different strains shows the overall
differential expression pattern of all variants across the brain
regions (Fig. 4). Plotting the expression level (E2DC(t)) for each
variant among the regions illustrates the differences quantitatively
and provides a visual pattern of regional expression (Figs. 5, S1 &
S2). For example, the expression pattern of the full length variant
mMOR-1A differed among the four strains. Its levels were high in
the thalamus and PAG of B6 mice, with lower levels in the
hippocampus and hypothalamus. In contrast, mMOR-1A expres-
sion in 129 mice was highest in the hypothalamus with similar high
levels in the striatum, thalamus, hippocampus and PAG. In SWR
mice mMOR-1A levels were highest in the hypothalamus with
lowest levels in the hippocampus.
Within a strain, the regional expression patterns of some of the
variants were similar. For example, mMOR-1A, mMOR-1B1,
mMOR-1C, mMOR-1G, mMOR-1S and mMOR-1T expression
in the B6 mice was highest in the PAG and thalamus (Fig. 5). A
similar expression pattern in B6 mice was observed in other eleven
variants including mMOR-1B2, mMOR-1B3, mMOR-1B5,
mMOR-1F, mMOR-1i, mMOR-1K, mMOR-1L, mMOR-1M,
mMOR-1P, mMOR-1Q and mMOR-1Z (Figs. S1 & S2).
Figure 2. Heatmap of expression levels of OPRM1 splice variant mRNAs. The heatmap was generated by clustering Z-scores calculated from
the values (Log2 (E
2DC(t)) of individual variants across different strains/regions using R statistical language (2.15.0) (www.r-project.org), and plotting
based upon expression levels among the variants with enhanced heatmap function heatmap.2 from gplots package. Pfc: prefrontal cortex; Str:
striatum; Tha: thalamus; Hyp: hypothalamus; Hip: hippocampus; PAG: periaqueductal gray; BS: brainstem; Cb: cerebellum; Spc: spinal cord; WB: whole
brain. 129:129P3/J; B6: C56BL/6J; SJL: SJL/J; SWR: SWR/J. Expression level was indicated by Z-score.
doi:10.1371/journal.pone.0111267.g002
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However, other strains showed different patterns of variant
expression among the regions. For example, in SJL mice,
mMOR-1O expression was highest in the striatum with low levels
in the brainstem while mMOR-1C expression levels in these same
regions were opposite (Fig. 5).
In general, variant expression was low in the cerebellum and
prefrontal cortex, consistent prior in situ hybridization studies with
the full-length MOR-1 probe [47]. However, this was not
uniformly the case. In SWR mice, mMOR-1U expression was
greatest in the cerebellum (Fig. S2) while mMOR-1O was highest
in the prefrontal cortex (Fig. 5).
Strain-specific expression of OPRM1 splices variant
mRNAs in selected brain regions
Segregating variant expression by individual regions provides
another approach to visualize strain differences in different splice
variants, and reveals interesting comparisons (Figs. 6, 7, S3 & S4).
The heatmap shows broad differences in expression of individual
variants among the strains in most brain regions (Fig. 6), as does
quantitative graphing where the expression level (E2DC(t)) of each
variant was plotted by strains within each region (Figs. 7, S3 & S4).
Within a region on the heatmap, each column provides the
relative expression of the different variants within the strain
whereas the horizontal comparisons reveal interstrain differences
for a specific variant.
Overall, the expression level of the variants varied among the
mouse strains. For example, in the spinal cord, the expression of
mMOR-1A in SJL mice was higher than the other strains (Fig. 7).
However, in the striatum, 129 mice had the highest expression
level. In the thalamus the 6-TM variant mMOR-1N expression
was much higher in B6 mice than in other tree mouse strains,
contrasting to its expression in the PAG where SJL levels were
greater than other three strains (Fig. 7). The expression of the
single TM variant mMOR-1S was higher in SWR mice in most
brain regions including the spinal cord, hypothalamus, prefrontal
cortex, striatum, PAG and brainstem. Although this single TM
variant does not directly bind opioid receptors, it is pharmaco-
logically relevant in that it stabilizes the full length mMOR-1
variant and significantly contributes to morphine analgesia [48].
Finally, the expression patterns of the variants within a brain
region varied among the strains. For example, the spinal
expression of mMOR-1C, mMOR-1i and mMOR-1S in SWR
mice was far higher than other strains, while in SJL mice the
expression of mMOR-1A, mMOR-1E and mMOR-1L predom-
inated spinally (Figs. 7, S3 & S4). A similar scenario was observed
in the PAG where the expressions of mMOR-1B2, mMOR-1G,
mMOR-1M, mMOR-1P and mMOR-1T were much greater in
Figure 3. Expression levels of selected ten splice variants in brain regions of four mouse strains. Expression levels of (21)/(Log2 (E
2DC(t)))
of selected variants is plotted across regions using MS excel. Pfc: prefrontal cortex; Str: striatum; Tha: thalamus; Hyp: hypothalamus; Hip:
hippocampus; PAG: periaqueductal gray; BS: brainstem; Cb: cerebellum; Spc: spinal cord; WB: whole brain. 129:129P3/J; B6: C56BL/6J; SJL: SJL/J; SWR:
SWR/J.
doi:10.1371/journal.pone.0111267.g003
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B6 mice than the other strains, whereas mMOR-1N had its
highest expression in SJL mice (Figs. 7 & S4). In the striatum,
mMOR-1A, mMOR-1B2, mMOR-1B3, mMOR-1B5, mMOR-
1D, mMOR-1F, mMOR-1Q, mMOR-1T, mMOR-1V and
mMOR-1Z were most highly expressed in 129 mice (Figs. 7, S3
& S4). However, mMOR-1N and mMOR-1S were predominately
expressed in the striatum of SJL and SWR mice, respectively
(Fig. 7). In the thalamus, mMOR-1B3, mMOR-1B4, mMOR-1K,
mMOR-1N and mMOR-1R were most highly expressed in B6
mice, whereas the thalamus expression of mMOR-1V and
mMOR-1W in SJL mice was much higher than other strains
(Figs. 7, S3 & S4). Together, these results suggested strain-specific
alternative splicing of the OPRM1 gene.
Discussion
The identification of a vast array of splice variants of the m
opioid receptor gene has shown a complexity in opioid pharma-
cology far beyond what had previously been imagined. Autora-
diography provided the earliest means of examining the anatom-
ical distribution of m binding sites [49–52]. The distribution of m
opioid receptors was then examined immunohistochemically and
with in situ hybridation following the cloning of the receptor [53–
63]. While these studies have provided valuable insights into
opioid action, they all have limitations. Autoradiographic
approaches are functional in the sense that they require active
binding of ligand. Since the early studies utilized traditional m
radioligands, they detected all the full length 7-TM variants, but
none of the truncated ones, and were not able to distinguish
among the 7-TM variants. The early immunohistochemical
studies targeted the C-terminus of MOR-1, with most using an
epitope encoded by exon 4. These probes will detect the full length
variants MOR-1, MOR-1H, MOR-1i and MOR-1J, as well as the
6-TM variant MOR-1G which all share the exon 4 epitope, but
none of the other variants. Some studies have examined epitopes
from alternatively spliced C-terminals, but they, too, may have
labeled more than one species. For example, early studies
examined the labeling of a 7/8/9 epitope, assuming it corre-
sponded to mMOR-1C. Yet, subsequent cloning studies identified
mMOR-1M, a truncated 6-TM variant that also contains the 7/
8/9 epitope. The in situ hybridization studies using probes
targeting exons 2 and 3 detected all the 7-TM and 6-TM splice
variants, but not the single TM ones. Thus, each approach gives a
unique set of labeling. Theoretically, qPCR offers the ability to
identify an individual mRNA, but even PCR faces selectivity
challenges due to both 39 and 59 splicing and extensive overlap in
sequence among the variants.
We previously used traditional RT-PCR approaches to examine
the expression of OPRM1 splice variant mRNAs in brain regions
[25–28]. However, these early approaches provided only an
approximation of levels since they were not quantitative. Many of
these studies also were carried out prior to the identification of
additional variants with overlapping sequences. The present study
using SYBR green qPCR overcomes these limitations and more
Figure 4. Heatmap of regional expression OPRM1 splice variant mRNAs. The heatmap was generated by clustering Z-scores calculated from
the values (Log2 (E
2DC(t)) of individual variants across different strains/regions using R statistical language (2.15.0) (www.r-project.org), and plotting
based upon individual brain regions within each mouse strain with enhanced heatmap function heatmap.2 from gplots package. Pfc: prefrontal
cortex; Str: striatum; Tha: thalamus; Hyp: hypothalamus; Hip: hippocampus; PAG: periaqueductal gray; BS: brainstem; Cb: cerebellum; Spc: spinal cord;
WB: whole brain. 129:129P3/J; B6: C56BL/6J; SJL: SJL/J; SWR: SWR/J. Expression level was indicated by Z-score.
doi:10.1371/journal.pone.0111267.g004
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precisely quantifies the expression of OPRM1 splice variant
mRNAs. Using these assays, we investigated the expression profiles
of all OPRM1 splice variant mRNAs in various brain regions of
four inbred mouse strains, for the first time, a complete expression
mRNA profile. However, even this approach does not address
their expression at the protein level.
Although our current approach provides selectivity, dissecting
tissues from a limited of brain regions does not provide anatomical
resolution at the cellular level and provides only an incomplete
assessment of variant expression. Future studies using single cell
qPCR or more sophisticated in situ hybridization approaches may
overcome these limitations. However, the current studies provide
the first step toward our understanding of OPRM1 splice variant
expression in brain.
The abundance of the OPRM1 splice variant mRNAs covers a
wide range. These mRNA levels presumably reflect steady-state
levels that depend upon many factors that may vary over time,
including transcription, post-transcriptional modification and
mRNA degradation. The OPRM1 gene has two distinct
promoters, exon 1 and exon 11 promoters. Most of the exon 1
promoter-controlled variants involve 39 splicing, yielding unique
C-terminal sequences, and are quite abundant. They include
mMOR-1A, mMOR-1B1, mMOR-1C, mMOR-1O and mMOR-
1V. In contrast, the exon 11 promoter-controlled variants generate
6-TM variants and are expressed at lower levels. While the
promoters may influence mRNA expression, they cannot explain
all the differences. Within each promoter group, mRNA levels
vary, as shown by the far lower levels of mMOR-1B2 and
mMOR-1P levels than those of mMOR-1A, mMOR-1B1 and
mMOR-1C in the PAG, hypothalamus and hippocampus of B6
mice and the differences in the exon 11 promoter-controlled 6-TM
variants mMOR-1G, mMOR-1K and mMOR-1N.
mRNA stability also may impact expression levels. Of particular
interest is nonsense-mediated decay (NMD) that targets an mRNA
containing a premature stop codon located more than 50 nt
upstream of the last exon-exon junction [64,65]. Eight variants,
including mMOR-1E, mMOR-1F, mMOR-1Q, mMOR-1R,
mMOR-1T, mMOR-1V, mMOR-1W, and mMOR-1Z, are
Figure 5. Region-specific expressions of ten-selected OPRM1 splice variants. Each panel represents the regional expression of one variant in
four inbred mouse strains. Red bar: B6 mice; Green bar: 129 mice; Blue bar: SJL mice; Brown bar: SWR mice. Bars represent the mean of E2DC(t) values
6 S.E.M. Pfc: prefrontal cortex; Str: striatum; Tha: thalamus; Hyp: hypothalamus; Hip: hippocampus; PAG: periaqueductal gray; BS: brainstem; Cb:
cerebellum; Spc: spinal cord; WB: whole brain. mE1-2 represents all full-length 7-TM variants. Significant difference was calculated by Two-way
ANOVA with Tukey’s multiple comparisons test for each variant (Prism 5.0). The results of the statistical analysis were listed in Table S3. The expression
profiles of the other 19 OPRM1 splice variants are shown in Figures S1 & S2.
doi:10.1371/journal.pone.0111267.g005
Figure 6. Heatmap of expression of OPRM1 splice variant mRNAs among four inbred mouse strains. The heatmap was generated by
clustering Z-scores calculated from the values (Log2 (E
2DC(t)) of individual variants across different strains/regions using R statistical language (2.15.0)
(www.r-project.org), and plotting based upon individual strains within each brain region with enhanced heatmap function heatmap.2 from gplots
package. Pfc: prefrontal cortex; Str: striatum; Tha: thalamus; Hyp: hypothalamus; Hip: hippocampus; PAG: periaqueductal gray; BS: brainstem; Cb:
cerebellum; Spc: spinal cord; WB: whole brain. 129:129P3/J; B6: C56BL/6J; SJL: SJL/J; SWR: SWR/J. Expression level was indicated by Z-score.
doi:10.1371/journal.pone.0111267.g006
OPRM1 Splice Variant mRNA Expressions in Four Inbred Mouse Strains
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Figure 7. Strain-specific expressions of OPRM1 splice variants. Each panel represents the expression of one variant in 10 regions of 4 inbred
mouse strains. Red bar: B6 mice; Green bar: 129 mice; Blue bar: SJL mice; Brown bar: SWR mice. Bars represent the mean of E2DC(t) values6 S.E.M. Pfc:
prefrontal cortex; Str: striatum; Tha: thalamus; Hyp: hypothalamus; Hip: hippocampus; PAG: periaqueductal gray; BS: brainstem; Cb: cerebellum; Spc:
spinal cord; WB: whole brain. Significant difference was calculated by Two-way ANOVA with Tukey’s multiple comparisons test for each variant. The
results of the statistical analysis were listed in Table S3. The expression profiles of the other 19 OPRM1 splice variants are shown in Figures S3 & S4.
doi:10.1371/journal.pone.0111267.g007
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potential targets of NMD. However, the variability of expression
among these variants implies that NMD is not solely one factor
among many influencing expression levels.
mRNA levels may not correlate with either their corresponding
protein expression or with their pharmacological importance. For
example, immunostaining by an exon 7/8/9-specific antisera that
label mMOR-1C and mMOR-1M was as robust as that seen with
the exon 4-specific antisera labeling mMOR-1, mMOR-1H,
mMOR-1i and mMOR-1J despite great differences in their
respective mRNA levels [23,24]. The lack of correlation between
mRNA and protein levels also may involve many factors. The
association of the different mRNAs with polyribosomes can vary
widely (Z. Lu, J. Xu, G.W. Pasternak, and Y.X. Pan, unpublished
data), suggesting the differential regulation of the variants at the
translational level. Other evidence indicates that the stability of the
variants at the protein level is dependent upon a range of factors.
For example, internalization and recycling of the receptors varies
among the variants [31] and co-expression of single TM splice
variants stabilizes MOR-1 protein levels, decreasing its degrada-
tion, extending its half-lives and thereby increasing its overall levels
[48]. Therefore, it will be important to develop a reliable and an
accurate method for determining protein expression of these
OPRM1 splice variants in the future.
mRNA levels do not necessarily correlate with pharmacological
relevance. For example, mMOR-1D has been implicated in
morphine-induced itch through its dimerization with gastrin-
releasing peptide receptor (GRPR) [66] despite its low mRNA
levels. Exon 11-associated 6-TM variants are also among the low
abundant transcripts. Yet, an exon 11 knockout mouse model
indicates a key role of these 6-TM variants in the analgesic actions
of a range of opioids, including heroin, morphine-6b-glucuronide,
fentanyl, levorphanol and buprenorphine [33,34]. These 6-TM
variants also are critical in the actions of a novel class of opioid
analgesic exemplified by 39-iodobenzoyl-6b-naltexamide
(IBNtxA), which is interesting since IBNtxA produces potent
analgesia without many traditional opioid side-effects such as
respiratory depression, physical dependence and reward behavior
[34]. The importance of 6-TM variants is further supported by
recent studies showing the rescue of IBNtxA analgesia in knockout
mice lacking 6-TM variants that are insensitive to IBNtxA by the
lentiviral-mediated delivery of a 6-TM variant, mMOR-1G (Z.
Lu, J. Xu, G. Rossi, G.W. Pasternak, and Y.X. Pan, unpublished
observations).
Our data also demonstrate variability in the expression of
OPRM1 splice variants in different strains. The importance of
genetic backgrounds in opioid pharmacology is becoming
increasingly appreciated. The four strains chosen for evaluation
differ in their sensitivity to morphine analgesia, with AD50 values
ranging from 6.8 mg/kg in C57BL/6 and 7.2 mg/kg in SJL to
13.7 mg/kg in 129P3 and 18.7 mg/kg in SWR mice [36]. They
also differ in the development of tolerance to chronic morphine
dosing of over three days, with analgesic shifts of 0.8 in the 129P3
mice to 2.2 in the SJL mice, 5 in SWR mice and 7.2 in the
C56BL/6 mice [36]. Dependence, measured by jumping following
naloxone precipitated withdrawal, also varies with the 129P3 and
SJL mice showing virtually no jumping with moderate levels of
jumping in the C57BL/6 mice and the most in the SWR mice
[35]. Although four strains is a very limited sample, it is interesting
that linear regression analysis correlating mRNA expression levels
with 1) morphine analgesia using half-maximal analgesic doses
(AD50), 2) morphine tolerance using the shift in AD50 fold with
chronic dosing over three days or [36] or 3) physical dependence
determined by jump scores from naloxone-precipitated withdrawal
[35] revealed strong correlations for some of the variants (r2.0.90;
Fig. S5), raising questions regarding the functional relevance of the
variants in these brain regions. While intriguing, these correlations
must be interpreted cautiously and require additional studies.
Recently, we observed that long-term morphine treatment in CD-
1 mice markedly upregulates a number of OPRM1 splice variants
in various brain regions, as determined by the qPCR assays
described here (J. Xu, A.J. Faskowitz, G.C. Rossi, M. Xu, Z. Lu,
Y.-X Pan and G.W. Pasternak, submitted). Considering the
variability in mRNA expression among the current strains of mice,
it will be interesting to compare morphine effects on the expression
of OPRM1 splice variants in these inbred mice.
Why the pattern of the variant expression in these four inbred
mouse strains containing the same single-copy OPRM1 gene
varies is not clear. Presumably, the strains differ in their
modulation of the promoters and alternative splicing machinery.
These may reflect genetic variations, such as single nucleotide
polymorphisms (SNPs), deletions, insertions and transposon
elements. Recently, we identified a heroin addiction severity-
associated intronic SNP that modulates alternative splicing of the
human OPRM1 variants via hnRNPH interaction [67]. Further
identifying the genetic variations that modulate the strain-specific
OPRM1 alternative splicing will greatly advance our knowledge
not only on the OPRM1 alternative splicing, but also on
alternative splicing in general.
Supporting Information
Figure S1 Expression levels of additional ten OPRM1
splice variants in brain regions of B6, SJL and SWR
mice. Each panel represents the regional expressions of one
variant in four inbred mouse strains. Red bar: B6 mice; Green bar:
129 mice; Blue bar: SJL mice; Brown bar: SWR mice. Bars
represent the mean of E2DC(t) values 6 S.E.M. Pfc: prefrontal
cortex; Str: striatum; Tha: thalamus; Hyp: hypothalamus; Hip:
hippocampus; PAG: periaqueductal gray; BS: brainstem; Cb:
cerebellum; Spc: spinal cord; WB: whole brain. Significant
difference was calculated by Two-way ANOVA with Tukey’s
multiple comparisons test for each variant. The results of the
statistical analysis were listed in Table S3.
(TIF)
Figure S2 Expression levels of additional nine OPRM1
splice variants in brain regions of B6, SJL and SWR
mice. Each panel represents the regional expressions of one
variant in four inbred mouse strains. Red bar: B6 mice; Green bar:
129 mice; Blue bar: SJL mice; Brown bar: SWR mice. Bars
represent the mean of E2DC(t) values 6 S.E.M. Pfc: prefrontal
cortex; Str: striatum; Tha: thalamus; Hyp: hypothalamus; Hip:
hippocampus; PAG: periaqueductal gray; BS: brainstem; Cb:
cerebellum; Spc: spinal cord; WB: whole brain. Significant
difference was calculated by Two-way ANOVA with Tukey’s
multiple comparisons test for each variant. The results of the
statistical analysis were listed in Table S3.
(TIF)
Figure S3 Strain-specific expressions of additional ten
OPRM1 splice variants. Each panel represents the expression
of one variant among four mouse strains in ten brain regions. Red
bar: B6 mice; Green bar: 129 mice; Blue bar: SJL mice; Brown
bar: SWR mice. Bars represent the mean of E2DC(t) values 6
S.E.M. Pfc: prefrontal cortex; Str: striatum; Tha: thalamus; Hyp:
hypothalamus; Hip: hippocampus; PAG: periaqueductal gray; BS:
brainstem; Cb: cerebellum; Spc: spinal cord; WB: whole brain.
mE1-2 represents all full-length 7TM variants. Significant
difference was calculated by Two-way ANOVA with Tukey’s
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multiple comparison for each variant. The results of the statistical
analysis were listed in Table S3.
(TIF)
Figure S4 Strain-specific expressions of additional nine
OPRM1 splice variants. Each panel represents the expression
of one variant among four mouse strains in ten brain regions. Red
bar: B6 mice; Green bar: 129 mice; Blue bar: SJL mice; Brown
bar: SWR mice. Bars represent the mean of E2DC(t) values 6
S.E.M. Pfc: prefrontal cortex; Str: striatum; Tha: thalamus; Hyp:
hypothalamus; Hip: hippocampus; PAG: periaqueductal gray; BS:
brainstem; Cb: cerebellum; Spc: spinal cord; WB: whole brain.
Significant difference was calculated by Two-way ANOVA with
Tukey’s multiple comparison for each variant. The results of the
statistical analysis were listed in Table S3.
(TIF)
Figure S5 Correlation of the expression levels of
OPRM1 splice variant mRNAs with morphine-induced
analgesia, tolerance and physical dependence in four
inbred mouse strains. A & B: Correlation of the expression
levels of OPRM1 splice variant mRNAs with morphine analgesia
in four inbred mouse strains. The square of the correlation
coefficient (r2) listed was obtained from linear regression analysis
(Prizm 5.0) between expression level (E2DC(t) *104) values (mean 6
S.E.M.) for each variant in the indicated brain region and
morphine analgesia potency (log (AD50)). The AD50 (mg/kg)
values in B6, SJL, 129 and SWR mice were 6.8, 7.2, 13.7 and
18.7, respectively [36]. C & D: Correlation of the expression levels
of OPRM1 splice variant mRNAs with morphine tolerance in four
inbred mouse strains. The square of the correlation coefficient (r2)
listed was obtained from linear regression analysis (Prizm 5.0)
between expression level (E2DC(t) *104) values (mean6 S.E.M.) for
each variant in the indicated brain region and morphine AD50
shift before and after chronic morphine treatment (log (Morphine
AD50 shift)). The AD50 shift values in 129, SJL, SWR and B6 mice
were 0.8, 2.2, 5 and 7.2, respectively [36]. E & F: Correlation of
the expression levels of OPRM1 splice variant mRNAs with
morphine-induced physical dependence in four inbred mouse
strains. The square of the correlation coefficient (r2) listed was
obtained from linear regression analysis (Prizm 5.0) between
expression level (E2DC(t) *104) values (mean 6 S.E.M.) for each
variant in the indicated brain region and jumping scores after
chronic morphine treatment followed by naloxone precipitated
withdrawal (log (Jumps/15 min)). The jumping scores in 129, SJL,
B6 and SWR mice were 7, 16, 60 and 200, respectively [35]. All
the variants listed have an r2 value over 0.90. A positive slope
indicates that the more expression of the variants, the more AD50
values (the less potent) or the more AD50 value shifts (the more
tolerant) or the more jumps (the more dependent) are. A negative
slope shows opposite relationships. Pfc: prefrontal cortex; Str:
striatum; Hyp: hypothalamus; Hip: hippocampus; PAG: periaq-
ueductal gray; BS: brainstem; Spc: spinal cord; WB: whole brain.
(TIF)
Table S1 SYBR green qPCR assay. SYBR green qPCR
assay for each variant was established as described in Materials
and Methods. Optimized conditions including primers and their
locations, thermal cycle condition, amplicon size and efficiency are
listed. SP: sense primer; AP: antisense primer.
(XLSX)
Table S2 Expression levels of OPRM1 splice variants.
Normalized expression level for each variant was calculated as
E2DC(t), where E is efficiency listed in Table S1, as described in
Materials and Methods. The mean of E2DC(t) values 6 S.E.M. is
listed.
(XLSX)
Table S3 Two-Way ANOVA analysis. Two-Way ANONVA
analysis with Tukey’s multiple comparisons test was performed as
described in Materials and Methods. Pfc: prefrontal cortex; Str:
striatum; Tha: thalamus; Hyp: hypothalamus; Hip: hippocampus;
PAG: periaqueductal gray; BS: brainstem; Cb: cerebellum; Spc:
spinal cord; WB: whole brain. For each variant, left tables are
regional comparisons in each inbred mouse strain, and right
tables, strain comparisons in each brain region. p values listed in
tables are: *: p,0.05; **: p,0.01; ***: p,0.001; ****: p,0.0001.
(XLSX)
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